ロード中...
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
The epothilone B analog, ixabepilone, demonstrates low susceptibility to drug resistance mechanisms and has demonstrated clinically meaningful efficacy in patients refractory to other chemotherapeutic options. Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2955910/ https://ncbi.nlm.nih.gov/pubmed/20886213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1467-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|